Introduction {#sec1}
============

Dry eye is a chronic multifactorial disorder, and is characterized by ocular surface inflammation and inadequate production of tears.[@bib1], [@bib2], [@bib3] It is the most common cause of ophthalmology visits in daily practice and has recently been noticed as a major problem in public health.[@bib4], [@bib5], [@bib6] Dry eye is an important complication of intraocular surgeries including cataract surgery (phacoemulsification).[@bib7], [@bib8] This complication can lead to patient dissatisfaction even after a non-complicated cataract surgery.[@bib9], [@bib10], [@bib11], [@bib12] Patients are more likely to complain from discomfort, burn, itching, red eye, photophobia, or even temporary blurring of vision.[@bib13], [@bib14]

The etiology of dry eye after cataract surgery is not clearly understood; however, various mechanisms have been proposed that might affect ocular surface environment after phacoemulsification and contribute to the development of dry eye. Eye drops and topical anesthesia containing preservatives such as benzalkonium chloride have been proven to negatively affect the corneal epithelium.[@bib15], [@bib16] Exposure to the light emitted from the operating microscope might be another factor causing dry eye after surgery.[@bib15] The normal organization of the corneal innervation can also be disrupted during the procedure that might lead to pathologic changes of the cornea and, consequently, the discomforts associated with dry eye.[@bib17]

As time passes after surgery, inflammation decreases, and patients\' symptoms alleviate. We should notice this critical early postoperative period and manage the dry eye-related symptoms. In this period, topical artificial tears and low potent steroids are the most common drugs to control inflammation and dry eye symptoms. The problem with artificial tears is their incomplete and temporary effect. The problem with topical steroids is their long list of side effects in long-term use, so it would be desirable to control inflammation with an alternative steroid sparing drug like anti-inflammatory omega-3 supplements with evidence in their different systemic benefits in elderly patients.[@bib18], [@bib19]

Docosahexaenoic acid (DHA) is an essential omega-3 polyunsaturated fatty acid that is necessary for the development of cognitive functions, reducing the risk factor for cardiovascular diseases, decreasing acute and chronic inflammation, and inducing anti-microbial resistance.[@bib18], [@bib19] Mounting evidence also has shown potential advantages of polyunsaturated fatty acid on the human eye.[@bib19], [@bib20], [@bib21], [@bib22]

Artificial tears are the mainstay of treatment in this condition, but only yield temporary and partial relief. Dietary intake of essential fatty acids is an alternative treatment in patients with dry eye. These fatty acids are the precursors for the synthesis of eicosanoids, i.e. prostaglandins, thromboxanes, and leukotrienes, which play important roles in inflammatory cascades. Arachidonic acid (AA) is converted into 2-series prostaglandins and 4-series leukotrienes via the cyclooxygenase and 5-lipoxygenase enzymes, respectively. The production of these AA-derived mediators can be decreased by the dietary intake of omega-3 fatty acid or eicosapentaenoic acid (EPA) through a process of competitive enzyme inhibition, shifting the balance towards a less inflammatory state.[@bib23] The effectiveness of anti-inflammatory omega-3 polyunsaturated fatty acids in the treatment of dry eye syndrome has been shown in multiple studies.[@bib24], [@bib25], [@bib26], [@bib27], [@bib28] However, few have simultaneously assessed the changes in tear film osmolarity, ocular surface disease index (OSDI), tear break up time (TBUT), and Schirmer\'s test in patients taking omega-3 fatty acids supplementation as an adjuvant treatment for dry eye syndrome following cataract surgery in a clinical trial. Accordingly, to do so, we aimed to conduct the present survey.

Methods {#sec2}
=======

All patients with new onset dry eye symptoms (foreign body sensation, burning, itching, red eye, photophobia, or blurring of vision) with a history of recent cataract surgery via phacoemulsification were enrolled in this study. Patients were recruited between September 2013 and May 2014 during ophthalmologic appointments at the study center. Exclusion criteria of this study were history of ocular trauma, uveitis, other previous ocular surgeries, contact lens wearing in the previous 2 years, systemic diseases that are associated with dry eye syndrome including diabetes, rheumatoid arthritis and Sjogren\'s syndrome, existing dry eye symptoms prior to cataract surgery, and considerable change in lifestyle with an impact on ocular surface diseases (e.g., computer use) during the postoperation period.

This study was a parallel group randomized controlled trial and conducted based on principles of the Declaration of Helsinki. The study protocol was supervised and approved by the Ethical Committee of Tehran University of Medical Sciences. Iran Registry of Clinical Trials (IRCT) Number: 2013062413567.$$N = \frac{2 \times \left( {Z_{1 - \alpha} + Z_{1 - \beta}} \right)^{2} \times \sigma^{2}}{d^{2}}$$

Utilizing the above formula,[@bib29] *α* = 0.05, *β* = 0.2 (CI = 95% and power = 80%) and also considering previous studies, the expected difference of osmolarity of *d* = 13 between the two groups was *σ* = 8. The sample size was calculated with 20 patients in each group. However, in order to reduce the risk of loss to follow-up, we decided to recruit at least 30 patients in each group.

Patients were randomly allocated into two groups using urn randomization. In the control group, patients were treated with standard therapy of dry eye (Artelac artificial tears every 4 h -- Dr. Gerhard Mann company, Germany -- and Betamethasone 0.1% eye drops every 8 h) for one month. In the treatment group, omega-3 dietary supplement (1000 mg every 8 h, Advanced^®^ Canada, each capsule containing 180 mg EPA and 120 mg DHA) was added to conventional therapy. Patients filled the standard questionnaire for OSDI, which is an instrument to quantify the severity of dry eye symptoms. OSDI questionnaire was scored from 0 to 100 (100 being the most severe disease). All measurements were done by a single person (M.M), and the physician in charge of collecting outcome data was kept blinded to the allocation.

TBUT was done after instillation of 5 μL of 2% sodium fluorescein without any irritation and manipulation of the patients\' ocular surface. We measured the mean time between last blinking and the first appearance of a dark spot in tear film in slit-lamp examination. The mentioned test was repeated 3 times solely on the affected eye, and the mean value was recorded. Participants then waited for at least 45 min, and 5 min Schirmer\'s test without topical anesthesia was done. Tear osmolarity was measured obtaining 50 nL of patient\'s tear and using Tearlab™ osmometer. All examinations were done during morning hours, and the patients were prohibited from using any topical drugs for at least 3 h prior to visits. All statistical analyses were performed by SPSS (IBM Corp. Released 2013. IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp.), using Student t-test, paired *t*-test and analysis of variance (ANOVA). A *P*-value of less than 0.05 was considered statistically significant.

Results {#sec3}
=======

In total, sixty-three eyes of 48 patients met our inclusion criteria and were enrolled in this study. Among 63 eyes, 31 eyes were randomly allocated in the control group, and 32 eyes were placed in the treatment group; however, 2 eyes in the control group were excluded due to the missed follow-up, so, analysis was performed on 29 and 32 eyes. The difference between the mean postoperative time was 1.59 ± 1.58 years (range: 20 days to 7 years) in this study. There was not any statistically significant difference between the control and treatment groups with regard to the mean postoperative time (1.61 ± 1.60 and 1.57 ± 1.57 years, respectively, *P* = 0.930). Mean patient age in this study was 63.78 ± 11.74 years. Mean patient age in the control group was 67.81 ± 9.62 years (range: 39--81) and 59.75 ± 11.57 years (range: 37--82) in the treatment group, which was significantly different comparing the two groups (*P* = 0.003). Demographic data is presented in [Table 1](#tbl1){ref-type="table"}.

As for baseline indices, there was no significant difference in TBUT, Schirmer\'s test, mean tear osmolarity, and mean OSDI between the two study groups (*P* = 0.687, *P* = 0.582, *P* = 0.906, and *P* = 0.635, respectively) ([Table 2](#tbl2){ref-type="table"}). These findings reflect the similarity between the two groups regarding dry eye severity.

Mean pre-treatment TBUT in both the control and treatment groups improved significantly after treatment (*P* = 0.010 and *P* \< 0.001, respectively). However, TBUT drift was significantly higher in the treatment group in comparison to the control (*P* = 0.038) ([Table 3](#tbl3){ref-type="table"}, [Table 4](#tbl4){ref-type="table"}).

Mean pre-treatment Schirmer in the control group was 3.50 ± 3.13 mm (range: 0--13), which changed insignificantly after treatment to 3.85 ± 2.88 mm (range: 1--7) (*P* = 0.551, CI 95%: −0.81 to 0.44). Mean Schirmer in the treatment group changed insignificantly from 2.96 ± 3.39 mm (range: 1--15) at baseline to 4.96 ± 2.84 (range: 1--15) at final visit (*P* = 0.113, CI 95%: −2.25 to 0.25). There was no difference between the control and treatment groups regarding Schirmer\'s test at final visit (*P* = 0.155).

Mean tear film osmolarity did not change significantly in the control group (*P* = 0.157). However, the respective value improved significantly from 315.40 ± 17.06 osmol/L (range: 279--340) to 296.90 ± 14.39 osmol/L (range: 260--310) in the treatment group (*P* \< 0.001).

Mean pre-treatment OSDI improved significantly at final visit in both the control and treatment groups (*P* = 0.003 and *P* \< 0.001, respectively).

It is noteworthy to mention that the mean OSDI improvement was significantly higher in the treatment group in comparison to the control group (*P* = 0.026).

Discussion {#sec4}
==========

This randomized clinical trial demonstrates the positive effect of omega-3 fatty acids in the treatment of dry eye syndrome in terms of qualitative objective and subjective dry eye indices after cataract surgery.

Dry eye is an important complication of ocular surgeries including cataract and refractive surgery. As patients who undergo cataract surgery are older than refractive surgery candidates and have more comorbidities, they may experience even more severe post-surgical dry eye.[@bib7], [@bib8]

This complication leads to patient complaints even after a non-complicated cataract surgery.[@bib9], [@bib10], [@bib11], [@bib12] Dry eye after eye surgeries can negatively influence the quality of life by causing eye discomfort, burning, itching, red eye, photophobia, or even temporary blurring of vision.[@bib13], [@bib14] Post-surgical dry eye can be triggered by different mechanisms, one of the most important of which is post-surgical inflammation.[@bib24], [@bib25], [@bib26], [@bib27], [@bib28]

Long chain fatty acids modulate the AA pathway and reduce inflammatory response. Omega-3 is considered an essential fatty acid that should be supplemented in diet and cannot be produced in the body.[@bib18]

Dry eye syndrome is a multifactorial disease, affecting tears and the ocular surface, accompanied by increased osmolarity of tear film, and inflammation of the ocular surface.[@bib30] DHA promotes synthesis of anti-inflammatory prostaglandins such as prostaglandin E3 and relieves dry eye symptoms.[@bib22]

Several studies have investigated the role of oral supplement of omega-3 fatty acids in the treatment of dry eye syndrome as an anti-inflammatory agent. Adding omega-3 has shown to increase tear production.[@bib24], [@bib25], [@bib26], [@bib27] Another suggested mechanism of omega-3 in the treatment of dry eye syndrome is changing the fatty acid composition of meibomian glands and therefore, the properties of their secretions.[@bib31], [@bib32] By these two different mechanisms, omega-3 fatty acids have shown to be effective in the treatment of dry eye syndrome. In a large cross-sectional study, Miljanović et al. have observed a lower incidence of dry eye symptoms in women with a higher dietary intake of omega-3.[@bib33]

In this study, OSDI and TBUT showed significant improvement in both the control and treatment groups, but this improvement was significantly higher in the treatment group in comparison to the control group for OSDI, TBUT, and tear osmolarity (which all cause improvement in tear film "quality") ([Fig. 1](#fig1){ref-type="fig"}, [Fig. 2](#fig2){ref-type="fig"}, [Fig. 3](#fig3){ref-type="fig"}).

These results illustrated that supplementing the diet with high amounts of omega-3 polyunsaturated fatty acids decreases dry eye symptoms after cataract surgery and increases tear film stability.

In our study, tear film osmolarity and consequently Schirmer\'s test results did not change significantly in the control group, but osmolarity showed significant improvement in the treatment group (*P* \< 0.001). Despite clinically considerable improvement in mean Schirmer\'s test of the treatment group (from 3.96 ± 3.39 to 4.96 ± 2.84), these results were not significant statistically.

Kangari et al.[@bib25] showed that adding omega-3 supplements to standard treatment of non-surgically-induced dry eye syndrome would significantly improve OSDI, TBUT, and Schirmer\'s test results. We observed similar results in post-cataract surgery dry eye syndrome for OSDI and TBUT, but in our study, there was not any statistically significant higher improvement in the treatment group in Schirmer\'s test, which is a quantitative tear film index (*P* = 0.155). It seems that omega-3 supplementation has positive effects on tear film quality rather than its quantity in surgically-induced dry eye syndrome. It could be explained by the more important role of inflammation in surgically-induced dry eye. Although inflammation could lead to the decreased production of tears, studies demonstrated conflicting results of anti-inflammatory medication in improvement of Schirmer\'s test[@bib24], [@bib25], [@bib26], [@bib30].

A possible explanation for this discrepancy could be in the homogenous studied population, with those with longer lasting inflammation and irreversible damage of lacrimal gland, showing the least improvement.

Although there are some studies investigating the effect of omega-3 on post-surgical dry eye,[@bib28], [@bib34] to our knowledge, this is the first study exploring the impact of omega-3 oral supplementation on cataract surgery induced dry eye.

Ong et al.\'s study on the effect of omega-3 fatty acids in the treatment of dry eye syndrome after photorefractive keratectomy concluded that adding omega-3 to standard treatment can lead to a significant higher improvement in epithelial healing, TBUT, and visual acuity. In their study, all patients in the treatment group reached visual acuity of 20/20, but only 4 patients in the control group reached this level of visual acuity.[@bib28] Our study also demonstrated significant improvement in tear osmolarity and alleviation of symptoms measured by OSDI, in addition to improve TBUT, with oral supplement of omega-3 combined with conventional therapy.

As for limitations to our study, lack of placebo could affect the observed response driven from oral medication which was missing in the control group. A long post-operative period in some cases might also have restricted our study due to possible confounding factors. We also excluded patients suffering from dry eye who underwent other type of cataract surgeries such as extracapsular cataract extraction (ECCE) or intracapsular cataract extraction (ICCE). Further randomized placebo-controlled clinical trials and subsequent systematic reviews can help in better illustration of the effects of supplementary omega-3 in the treatment of post-cataract surgery dry eye.

In conclusion, this randomized clinical trial shows the effectiveness of omega-3 supplements in the management of dry eye syndrome after cataract surgery in terms of both subjective and objective measurements. Therefore, it could be safely added to the postoperative protocols following cataract surgery to reduce the incidence of post-operative dry eye syndrome.
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###### 

Demographic data.

  Characteristic             Control group                        Treatment group                       Overall
  -------------------------- ------------------------------------ ------------------------------------- --------------------------------------
  Age                        67.81 ± 9.62 years (range: 39--81)   59.75 ± 11.57 years (range: 37--82)   63.78 ± 11.74 years (range: 37--82)
  *P* value: 0.003                                                                                      
  Sex                        17 (77%) females, 6 (23%) males      21 (84%) females, 4 (16%) males       38 (79.1%) females, 10 (20.9%) males
  Eye                        13 (44.8%) OS, 16 (55.2%) OD         16 (50%) OS, 16 (50%) OD              29 (47.5%) OS, 32 (52.5%) OD
  Mean post-operative time   1.61 ± 1.60 years                    1.57 ± 1.57 years                     1.59 ± 1.58 years
  *P* value: 0.930                                                                                      

###### 

Comparison of tear beak up time (TBUT), Schirmer, osmolarity and OSDI in treatment and control groups.

  Characteristic   Control/treatment                  Control                            Treatment                          *P*
  ---------------- ---------------------------------- ---------------------------------- ---------------------------------- -------
  TBUT             Pre-treatment                      6.67 ± 1.36 s (3--8)               4.87 ± 2.22 s (2--11)              0.687
  Post-treatment   6.03 ± 2.26 s (4--11)              7.65 ± 3.26 s (2--15)              *0.038*                            
  Schirmer         Pre-treatment                      3.50 ± 3.13 mm (0--13)             3.96 ± 3.39 mm (1--15)             0.582
  Post-treatment   3.85 ± 2.88 mm (1--15)             4.96 ± 2.84 mm (1--11)             0.155                              
  Osmolarity       Pre-treatment                      316.66 ± 8.50 osmol/L (308--325)   315.4 ± 17.06 osmol/L (279--340)   0.906
  Post-treatment   311.33 ± 6.35 osmol/L (304--315)   296.9 ± 14.39 osmol/L (260--310)   *0.01*                             
  OSDI             Pre-treatment                      32.99 ± 19.03 (3.12--77.77)        35.32 ± 18.99 (7.50--77.77)        0.635
  Post-treatment   25.43 ± 14.49 (0--58.33)           16.31 ± 13.72 (2.77--47.22)        *0.026*                            

TBUT: tear beak up time, OSDI: ocular surface disease index.

###### 

Comparison of tear beak up time (TBUT), Schirmer, osmolarity and ocular surface disease index (OSDI) in control group.

  Characteristic   Mean ± SD (range)                  Confidence interval 95%            *P*              
  ---------------- ---------------------------------- ---------------------------------- ---------------- -------
  TBUT             Pre-treatment                      6.67 ± 1.36 s (3--8)               −2.32 to −3.39   0.010
  Post-treatment   6.03 ± 2.26 s (4--11)                                                                  
  Schirmer         Pre-treatment                      3.50 ± 3.13 mm (0--13)             −0.81 to 0.44    0.551
  Post-treatment   3.85 ± 2.88 mm (1--15)                                                                 
  Osmolarity       Pre-treatment                      316.66 ± 8.50 osmol/L (308--325)   −5 to 15.67      0.157
  Post-treatment   311.33 ± 6.35 osmol/L (304--315)                                                       
  OSDI             Pre-treatment                      32.99 ± 19.03 (3.12--77.77)        3.14--13.24      0.003
  Post-treatment   25.43 ± 14.49 (0--58.33)                                                               

TBUT: tear beak up time, OSDI: ocular surface disease index.

###### 

Comparison of tear beak up time (TBUT), Schirmer, osmolarity and ocular surface disease index (OSDI) before and after treatment with omega-3.

  Characteristic   Mean ± SD (range)                  Confidence interval 95%            *P*              
  ---------------- ---------------------------------- ---------------------------------- ---------------- --------
  TBUT             Pre-treatment                      4.87 ± 2.22 s (2--11)              −3.63 to −1.51   0.0001
  Post-treatment   7.65 ± 3.26 s (2--15)                                                                  
  Schirmer         Pre-treatment                      3.96 ± 3.39 mm (1--15)             −2.25 to 0.25    0.113
  Post-treatment   4.96 ± 2.84 mm (1--11)                                                                 
  Osmolarity       Pre-treatment                      315.4 ± 17.06 osmol/L (279--340)   11.74 to 25.25   0.0001
  Post-treatment   296.9 ± 14.39 osmol/L (260--310)                                                       
  OSDI             Pre-treatment                      35.32 ± 18.99 (7.50--77.77)        9.64--21.19      0.0001
  Post-treatment   16.31 ± 13.72 (2.77--47.22)                                                            

TBUT: tear beak up time, OSDI: ocular surface disease index.
